Literatur
- 1
Ebrahim G J.
Resistance to antimalarials.
J Trop
Pediatr.
2002;
48
192-193
- 2
Hemmer C J, Kern P, Holst F G, Nawroth P P, Dietrich M.
Neither heparin nor acetylsalicylic acid influence the
clinical course in human Plasmodium falciparum malaria: a prospective
randomised study.
Am J Trop Med
Hyg.
1991;
45
608-612
- 3
Ittarat W, Pickard A L, Rattanasinganchan P. et al .
Recrudescence in artesunate-treated patients with falciparum
malaria is dependent on parasite burden not on parasite factors.
Am J
Trop Med
Hyg.
2003;
68
147-152
- 4
Jelinek T, Nothdurft H D, Von Sonnenburg F, Loscher T.
Long-term efficacy of primaquine in the treatment of vivax
malaria in nonimmune travelers.
Am J Trop Med
Hyg.
1995;
52
322-324
- 5
Lell B, Kremsner P G.
Clindamycin as an antimalarial drug: review of clinical
trials.
Antimicrob Agents
Chemother.
2002;
46
2315-2320
- 6
Prasad K, Garner P.
Steroids for treating cerebral malaria.
Cochrane
Database Syst
Rev.
2000;
CD000972
- 7
Riddle M S, Jackson J L, Sanders J W, Blazes D L.
Exchange transfusion as an adjunct therapy in severe
Plasmodium falciparum malaria: a meta-analysis.
Clin Infect
Dis.
2002;
34
1192-1198
- 8
Wesche D L, Schuster B G, Wang W X, Woosley R L.
Mechanism of cardiotoxicity of halofantrine.
Clin
Pharmacol
Ther.
2000;
67
521-529
- 9
White N.
The management of severe falciparum malaria.
Am J
Respir Crit Care
Med.
2003;
167
673-674
- 10
Wongsrichanalai C, Sirichaisinthop J, Karwacki J J. et al .
Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian
borders.
Southeast Asian J Trop Med Public
Health.
2001;
32
41-49
- 11
World Health Organization .
Severe falciparum malaria.
Trans R Soc Trop Med
Hyg.
2000;
94
(Suppl
1)
1-31
Prof. Dr. med. T. Löscher
Abteilung für Infektions- und Tropenmedizin
Leopoldstraße 5
80802 München
Phone: 089/21803517
Fax: 089/336112
Email: loescher@lrz.uni-muenchen.de